Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us.
In a quarter that was marked by the rapid spread of the COVID-19 pandemic, drug approvals continued (Table 1), but launching was a completely different…
The rapid spread of the coronavirus has revived a decades-old debate over pharmaceutical policy, with both sides doubling down on long-held views.
Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak…
Projections from EvaluatePharma are quoted by the study, showing that the sector will experience compound annual growth of 6.9% for global prescription drug sales.
With an estimated $5.4 billion in sunk costs in Brilinta, AstraZeneca will likely never turn a profit on the blood thinner with generics expected to hit the market in…
Research firm EvaluatePharma sees global sales of Enhertu in the $2 billion range in 2024, and Fumiyoshi Sakai of Credit Suisse Securities (Japan) predicts peak annual…
Analysts don’t see Libtayo making a big impression in the field, however – Evaluate Pharma forecasts the drug reaching revenues of just $600m by 2024, far behind Merck…
Zepsyre carries 2024 sales forecasts of $163 million, implying an NPV of $600 million, according to EvaluatePharma
Novo Nordisk shares recently popped, and Evaluate Pharma speculates that this was related to the company’s participation in the trial after the Danish newspaper Børsen…
The sell-side expects tafasitamab to generate 2024 revenue of $661 million, according to EvaluatePharma consensus.
EvaluatePharma has previously predicted that Ozempic could become a $2.2bn product by 2022, but other analysts think it could go even higher, perhaps reaching $3bn plus…
By 2024, the cost of gene therapies is expected to reach more than $16 billion in the United States, according to EvaluatePharma, which is both good news and bad news…
Bristol-Myers Squibb Co., fresh off completing one of the largest drug-industry mergers ever, is counting on the acquisition to pay off quickly with new products and…